Takeda Pharmaceutical Company has announced plans to initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist for Narcolepsy Type 1, in the first half of the fiscal year 2024. This follows a successful Phase 2b trial, which has paved the way for the drug's progression to late-stage testing, though it only supports treatment for one form of the disease. The move to rapidly advance TAK-861 into Phase 3 trials signifies Takeda's commitment to addressing narcolepsy, a sleep disorder that currently has limited treatment options.
Marfa Invitational has suffered IRS troubles and board member shuffling, but founder Michael Phelan is counting "Sleeping Figure" a victory. https://t.co/24dkd3ivm3
Takeda speeds narcolepsy drug to late-stage testing https://t.co/YM9yEOWdcY $TAK by @realJacobBell
Takeda speeds narcolepsy drug to late-stage testing https://t.co/NvdeYB9Cki by @realJacobBell $TAK $ALKS $JAZZ
Takeda’s narcolepsy work has finally yielded a phase 2b win, but the program only supports progression in one form of the disease. $TAK https://t.co/iz5vv8YCWt
$4502.JT | $TAK 🇯🇵 Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 https://t.co/VPiyUXBDIU https://t.co/1yLXlXkVWG